Eurofins Discovery Introduces Innovative DiscoveryAI SAFIRE: A New AI-Driven Platform for Drug Discovery Trained Using Proprietary Datasets
Eurofins Discovery , an industry-leading provider of products and services for drug discovery research, today announced the launch of DiscoveryAI SAFIRE (Suite of ADMET Predictions For In Silico Refinement and Evaluation).
- Eurofins Discovery , an industry-leading provider of products and services for drug discovery research, today announced the launch of DiscoveryAI SAFIRE (Suite of ADMET Predictions For In Silico Refinement and Evaluation).
- SAFIRE is an advanced platform that leverages proprietary datasets, artificial intelligence (AI), and machine learning (ML), offering a unique capability for expediting discovery.
- It’s proven effective in accelerating drug discovery projects from initial hit discovery through to lead optimization.
- For more details about SAFIRE’s benefits and significant value to the drug discovery community, visit eurofinsdiscovery.com/safire .